Compare SABS & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SABS | PRE |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | Hong Kong |
| Employees | 86 | 98 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.8M | 337.6M |
| IPO Year | N/A | N/A |
| Metric | SABS | PRE |
|---|---|---|
| Price | $3.71 | $18.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $10.75 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 830.5K | 228.6K |
| Earning Date | 05-12-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $108.69 |
| Revenue Next Year | N/A | $58.68 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.67 | $7.18 |
| 52 Week High | $6.60 | $23.63 |
| Indicator | SABS | PRE |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 47.63 |
| Support Level | $3.48 | $17.44 |
| Resistance Level | $4.10 | $21.81 |
| Average True Range (ATR) | 0.24 | 1.50 |
| MACD | 0.04 | -0.23 |
| Stochastic Oscillator | 61.80 | 31.76 |
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
Prenetics Global Ltd is a health sciences company dedicated to advancing consumer health. The consumer initiative is led by IM8, one of the world's fastest-growing supplement brands; Europa, one of the sports distribution companies in the USA; and CircleDNA, a direct-to-consumer DNA testing company. As the first consumer healthcare company to establish a Bitcoin treasury with its initial approximately $20 million Bitcoin purchase and board-approved comprehensive Bitcoin plan of action, Prenetics is pioneering the intersection of healthcare innovation and digital asset adoption.